Cardiologie [Cardiology]

Détails

Ressource 1Télécharger: 172-80_42323.pdf (642.53 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_7AE207FC0DDC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Cardiologie [Cardiology]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Kilani N., Haddad C., Lu H., Ghanbari F., Domenichini G., Pavon A.G., Tzimas G., Fournier S., Hullin R., Pascale P., Eeckhout E., Schwitter J., Pruvot E., Bouchardy J., Monney P., Muller O., Rutz T.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
27/01/2021
Peer-reviewed
Oui
Volume
17
Numéro
723
Pages
172-180
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
In 2020, new guidelines have been published by the European Society of Cardiology including those on non-ST-segment elevation acute coronary syndromes, atrial fibrillation and adult congenital heart disease. Regarding interventional cardiology, POPular TAVI opens the possibility of anti-platelet monotherapy after transcutaneous aortic valve replacement. EMPEROR-Reduced confirms the importance of SGLT2 inhibitors in the treatment of heart failure with reduced ejection fraction. Within the field of imaging, stress MRI has now become the first-line technique for the screening of coronary artery disease, demonstrating an excellent cost-benefit ratio. Finally, renin-angiotensin-aldosterone inhibitors do not appear to increase the risk of an infection by COVID-19.
Mots-clé
COVID-19, Cardiology, Heart Defects, Congenital, Humans, SARS-CoV-2
Pubmed
Création de la notice
04/09/2021 7:33
Dernière modification de la notice
13/02/2022 7:36
Données d'usage